Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233430 | 0.89 | TRPV4 (0.42) | KCNH2DRD2DRD3SCN9AALDH1A1 | |
| SCHEMBL3479732 | 0.88 | HTR3A (0.46) | KCNH2DRD2DRD3SCN9AALDH1A1 | |
| SCHEMBL3231984 | 0.88 | DRD2 (0.43) | KCNH2DRD2DRD3SCN9AALDH1A1 | |
| SCHEMBL3225536 | 0.88 | ALDH1A1 (0.43) | KCNH2DRD2DRD3SCN9AALDH1A1 | |
| SCHEMBL3229962 | 0.87 | KCNH2 (0.45) | KCNH2DRD2DRD3SCN9AALDH1A1 | |
| SCHEMBL3479806 | 0.86 | ALDH1A1 (0.41) | KCNH2DRD2DRD3SCN9AALDH1A1 | |
| SCHEMBL3228455 | 0.85 | ALDH1A1 (0.40) | KCNH2DRD2DRD3ALDH1A1HTR2A | |
| SCHEMBL3479544 | 0.84 | ALDH1A1 (0.40) | KCNH2DRD2DRD3SCN9AALDH1A1 | |
| SCHEMBL3233898 | 0.84 | ALDH1A1 (0.42) | KCNH2DRD2DRD3ALDH1A1CHRM5 | |
| SCHEMBL3229567 | 0.84 | DRD1 (0.55) | DRD2DRD3DRD1DRD5SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096546-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20100137287-A1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137287-A1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA1B, ADRB1, ADRA1D | KCNH2 537/4885DRD2 5/4885DRD3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.